180 related articles for article (PubMed ID: 26988130)
1. Investigational therapies for Ewing sarcoma: a search without a clear finding.
Vornicova O; Bar-Sela G
Expert Opin Investig Drugs; 2016 Jun; 25(6):679-86. PubMed ID: 26988130
[TBL] [Abstract][Full Text] [Related]
2. Ewing sarcoma: investigational mono- and combination therapies in clinical trials.
Gartrell J; Rodriguez-Galindo C
Expert Opin Investig Drugs; 2021 Jun; 30(6):653-663. PubMed ID: 33870845
[TBL] [Abstract][Full Text] [Related]
3. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.
van Maldegem AM; Bovée JV; Peterse EF; Hogendoorn PC; Gelderblom H
Eur J Cancer; 2016 Jan; 53():171-80. PubMed ID: 26765686
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.
Choy E; Butrynski JE; Harmon DC; Morgan JA; George S; Wagner AJ; D'Adamo D; Cote GM; Flamand Y; Benes CH; Haber DA; Baselga JM; Demetri GD
BMC Cancer; 2014 Nov; 14():813. PubMed ID: 25374341
[TBL] [Abstract][Full Text] [Related]
5. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
Kovar H
Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapies for advanced Ewing sarcoma family of tumors.
Jiang Y; Ludwig J; Janku F
Cancer Treat Rev; 2015 May; 41(5):391-400. PubMed ID: 25869102
[TBL] [Abstract][Full Text] [Related]
7. Ewing sarcoma family of tumors.
Maheshwari AV; Cheng EY
J Am Acad Orthop Surg; 2010 Feb; 18(2):94-107. PubMed ID: 20118326
[TBL] [Abstract][Full Text] [Related]
8. Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.
Owens C; Abbott LS; Gupta AA
Paediatr Drugs; 2013 Dec; 15(6):473-92. PubMed ID: 23760780
[TBL] [Abstract][Full Text] [Related]
9. Prospects and challenges for the development of new therapies for Ewing sarcoma.
Grohar PJ; Helman LJ
Pharmacol Ther; 2013 Feb; 137(2):216-24. PubMed ID: 23085431
[TBL] [Abstract][Full Text] [Related]
10. New strategies in ewing sarcoma: lost in translation?
Arnaldez FI; Helman LJ
Clin Cancer Res; 2014 Jun; 20(12):3050-6. PubMed ID: 24756371
[TBL] [Abstract][Full Text] [Related]
11. Analysis of prognostic factors in extraosseous Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital experience.
Orr WS; Denbo JW; Billups CA; Wu J; Navid F; Rao BN; Davidoff AM; Krasin MJ
Ann Surg Oncol; 2012 Nov; 19(12):3816-22. PubMed ID: 22739653
[TBL] [Abstract][Full Text] [Related]
12. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
13. Systematic review of phase-I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research.
Felix A; Berlanga P; Toulmonde M; Landman-Parker J; Dumont S; Vassal G; Le Deley MC; Gaspar N
Cancer Med; 2021 Mar; 10(5):1589-1604. PubMed ID: 33452711
[TBL] [Abstract][Full Text] [Related]
14. Ewing's sarcoma.
Karosas AO
Am J Health Syst Pharm; 2010 Oct; 67(19):1599-605. PubMed ID: 20852160
[TBL] [Abstract][Full Text] [Related]
15. Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.
Vormoor B; Curtin NJ
Curr Opin Oncol; 2014 Jul; 26(4):428-33. PubMed ID: 24840521
[TBL] [Abstract][Full Text] [Related]
16. Validation of a multi-modal treatment protocol for Ewing sarcoma--a report from the polish pediatric oncology group.
Raciborska A; Bilska K; Drabko K; Chaber R; Sobol G; Pogorzała M; Wyrobek E; Połczyńska K; Rogowska E; Rodriguez-Galindo C; Wożniak W
Pediatr Blood Cancer; 2014 Dec; 61(12):2170-4. PubMed ID: 25163763
[TBL] [Abstract][Full Text] [Related]
17. SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS.
Cohen IJ; Toledano H; Stein J; Kollender Y; Fenig E; Konen O; Bar-Sever Z; Issakov J; Feinmesser M; Avigad S; Ash S
Cancer Chemother Pharmacol; 2019 May; 83(5):859-866. PubMed ID: 30770960
[TBL] [Abstract][Full Text] [Related]
18. Potential approaches to the treatment of Ewing's sarcoma.
Yu H; Ge Y; Guo L; Huang L
Oncotarget; 2017 Jan; 8(3):5523-5539. PubMed ID: 27740934
[TBL] [Abstract][Full Text] [Related]
19. Survival and prognostic factors in adult patients with recurrent or refractory ewing sarcoma family tumours: a 13-years retrospective study in Turkey.
Yildiz I; Sen F; Ekenel M; Darendeliler E; Bavbek S; Agaoglu F; Ozger H; Eralp L; Bilgic B; Basaran M
In Vivo; 2014; 28(3):403-9. PubMed ID: 24815845
[TBL] [Abstract][Full Text] [Related]
20. Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma?
Redini F; Odri GA; Picarda G; Gaspar N; Heymann MF; Corradini N; Heymann D
Expert Opin Emerg Drugs; 2013 Sep; 18(3):339-52. PubMed ID: 23957761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
